What is MediBeacon?
MediBeacon is at the forefront of medical technology, focusing on the development of advanced fluorescent tracer agents and sophisticated transdermal measurement systems. Their flagship product, the Transdermal GFR System (TGFR), offers a non-invasive method for monitoring kidney function via a skin-placed sensor. This innovation targets a diverse clientele, including leading academic institutions, research organizations, contract research firms, and global pharmaceutical companies. MediBeacon's strategic objective is to enhance patient care and reduce healthcare expenditures across nephrology, gastroenterology, ophthalmology, and surgical specialties through its cutting-edge solutions.
How much funding has MediBeacon raised?
MediBeacon has raised a total of $114.2M across 8 funding rounds:
Debt
$5.1M
Series A
$3.5M
Unspecified
$5M
Private Equity
$22.4M
Series B
$33.6M
Series C
$10M
Debt
$4.6M
Other Financing Round
$30M
Debt (2012): $5.1M, investors not publicly disclosed
Series A (2013): $3.5M led by Missouri Technology, Helix Funds, and BioGenerator
Unspecified (2015): $5M, investors not publicly disclosed
Private Equity (2015): $22.4M, investors not publicly disclosed
Series B (2017): $33.6M backed by HC2
Series C (2017): $10M with participation from HC2
Debt (2018): $4.6M, investors not publicly disclosed
Other Financing Round (2019): $30M supported by Huadong Medicine
Key Investors in MediBeacon
HC2
HC2 is a diversified holding company with investments across various sectors including life sciences, telecommunications, and energy, indicating a strategic interest in companies with broad market potential.
Missouri Technology
The Missouri Technology Corporation is a public-private partnership focused on fostering high-tech companies in Missouri, particularly in life sciences, suggesting a focus on regional innovation and early-stage development.
Helix Funds
Helix Funds is a real estate investment management company, which is an unusual investor for a medtech firm. This may indicate a unique financing structure or a strategic partnership beyond traditional venture capital.
What's next for MediBeacon?
With a substantial infusion of capital, MediBeacon is poised for accelerated growth and market expansion. The recent major strategic investment signals confidence from backers in the company's trajectory and its potential to disrupt key areas of medical diagnostics. This financing is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the commercial reach of its TGFR system and other pipeline technologies. The company's focus on non-invasive monitoring aligns with a growing trend in healthcare towards patient-centric and cost-effective solutions, positioning MediBeacon for sustained advancement in the competitive medtech landscape.
See full MediBeacon company page
